Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.

OBJECTIVES Dyslipidemia associated with antiretroviral therapy is a common clinical problem among HIV-infected patients. Considering that the challenge of adherence to drugs (both antiretroviral and lipid lowering) may be substantial in routine HIV care, our objective was to evaluate the lipid-lowering effects of statins and fibrates in the management of HIV dyslipidemias in clinical practice setting. METHODS Retrospective review of 103 ethnically diverse dyslipidemic HIV patients on antiretroviral therapy treated with lipid-lowering drugs (using National Cholesterol Education and Prevention II [NCEP II] guidelines) who were followed for a median of 70 weeks. RESULTS An overall mean reduction of 16% in total cholesterol, 20% non-HDL cholesterol, and 18% in triglycerides was noted. There were no significant changes in HDL levels. On evaluation of the different drug classes, the mean (median) change in total cholesterol, were -9 (-7)% with fibrates, -11 (-14)% with statins and -23 (-22)% for dual therapy with fibrates and statins. The triglycerides decreased by -11 (-40)% in those treated with fibrates; -1 (-21)% in those with statins alone, and -32 (-42)% in those with dual therapy. Overall less than a fifth of patients reached the defined NCEP target goal reduction. On logistic regression analysis, only stopping protease inhibitors/ritonavir was independently associated with significant cholesterol reduction (OR: 10.14; 95% CI: 2.1-48.9; p < 0.005). CONCLUSION In a primary care setting, the use of statins and/or fibrates may add to the complexity of HIV care, with only modest lipid lowering effects.

[1]  R. Paredes,et al.  Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. , 2001 .

[2]  Ethan M Balk,et al.  Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. , 2002, JAMA.

[3]  K. Henry,et al.  Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities , 1998, The Lancet.

[4]  Dannae Brown,et al.  A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia , 2002, AIDS.

[5]  P. Hsyu,et al.  Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin , 2001, Antimicrobial Agents and Chemotherapy.

[6]  M. Radford,et al.  How do observational studies expand the evidence base for therapy? , 2001, JAMA.

[7]  J. Mallolas,et al.  Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Peter J. Neumann,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[9]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[10]  G. Stajich,et al.  Safety and Efficacy of HMG‐CoA Reductase Inhibitors for Treatment of Hyperlipidemia in Patients with HIV Infection , 2000, Pharmacotherapy.

[11]  A Ammassari,et al.  Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. , 2000, AIDS.

[12]  Rosario Palacios,et al.  Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. , 2002, Journal of acquired immune deficiency syndromes.

[13]  J. Wang,et al.  Hypertriglyceridemia in the acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[14]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[15]  J. Leonard,et al.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects , 2000, AIDS.

[16]  Margaret Ferley.  AIDS Policy & Law , 1993 .

[17]  P Langenberg,et al.  Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. , 2001, Archives of internal medicine.

[18]  M. Pendergrass,et al.  Nonhypoglycemic Effects of Thiazolidinediones , 2001, Annals of Internal Medicine.

[19]  R. Paredes,et al.  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  H. Pownall,et al.  Metabolic basis of HIV-lipodystrophy syndrome. , 2002, American journal of physiology. Endocrinology and metabolism.

[21]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[22]  W. K. Henry,et al.  Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  E. Braunwald,et al.  Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. , 2002, JAMA.

[24]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[25]  Rosario Palacios,et al.  Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. , 2002, Journal of acquired immune deficiency syndromes.

[26]  D. Musher,et al.  Severe Diabetes Associated with Protease Inhibitor Therapy , 1997, Annals of Internal Medicine.

[27]  Y. Shoenfeld,et al.  Antiinflammatory and immunomodulatory properties of statins , 2002, Immunologic research.

[28]  B. Gazzard,et al.  Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy , 2001, AIDS.

[29]  J. Tu,et al.  Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes , 2002 .

[30]  M. Shelton,et al.  Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. , 1999, AIDS.